Dr. Matthew Ingham, MD
Claim this profileColumbia University Medical Center
Studies Soft Tissue Sarcoma
Studies Skin Cancer
9 reported clinical trials
16 drugs studied
Area of expertise
1Soft Tissue Sarcoma
Stage IV
Stage III
2Skin Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Matthew Ingham, MD is currently running
Olaparib + Temozolomide
for Uterine Leiomyosarcoma
This phase II/III trial compares the effect of the combination of olaparib and temozolomide to the usual treatment (trabectedin and pazopanib) for uterine leiomyosarcoma that has spread to other places in the body (advanced) after initial chemotherapy has stopped working. Olaparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Temozolomide is in a class of medications called alkylating agents. It works by slowing or stopping the growth of tumor cells in the body. The combination of olaparib and temozolomide may work better than the usual treatment in shrinking or stabilizing advanced uterine leiomyosarcoma after initial chemotherapy has stopped working.
Recruiting1 award Phase 2 & 31 criteria
Tazemetostat + Doxorubicin
for Sarcoma
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue. Part 1 of this trial will evaluate the safety and the level of the study drug that the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare for each of the study drug combinations how long participants live without their disease getting worse. The study drug is called tazemetostat. The study will test tazemetostat in combination with doxorubicin compared to placebo (dummy treatment) in combination with doxorubicin. Doxorubicin is a current front line treatment for epithelioid sarcoma
Recruiting1 award Phase 312 criteria
More about Matthew Ingham, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Matthew Ingham, MD has experience with
- PD-1 Inhibitor
- CAB-ROR2-ADC
- BI 754091
- BI 1387446
- CAB-AXL-ADC
- CDK-002
Breakdown of trials Matthew Ingham, MD has run
Soft Tissue Sarcoma
Skin Cancer
Head and Neck Cancers
Breast Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Ingham, MD specialize in?
Matthew Ingham, MD focuses on Soft Tissue Sarcoma and Skin Cancer. In particular, much of their work with Soft Tissue Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Matthew Ingham, MD currently recruiting for clinical trials?
Yes, Matthew Ingham, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Matthew Ingham, MD has studied deeply?
Yes, Matthew Ingham, MD has studied treatments such as PD-1 inhibitor, CAB-ROR2-ADC, BI 754091.
What is the best way to schedule an appointment with Matthew Ingham, MD?
Apply for one of the trials that Matthew Ingham, MD is conducting.
What is the office address of Matthew Ingham, MD?
The office of Matthew Ingham, MD is located at: Columbia University Medical Center, New York, New York 10032 United States. This is the address for their practice at the Columbia University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.